Key facts
- Fertiga’s last known valuation is $14.0M (Jun 2025).
- It has raised $2.9M; the latest was Later Stage VC ($2.6M) in Jun 2025.
- Notable investors include Novalis Biotech, Vrije Universiteit Brussel.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Fertiga
- ·The full record, as it builds
Funding rounds
No funding rounds for Fertiga are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fertiga
Operator of a fertility test clinic intended to improve fertility treatment outcomes. The company's test provides helpful insights into the quality of eggs and predicts which egg has the potential to develop into a baby, enabling couples to minimize the cost, time, and stress of infertility treatments.
- Sector
- Healthcare
- HQ
- Lede, Belgium
- Founded
- 2017
- Employees
- 4
- Website
- fertiga.com/
- Ownership
- Privately Held (backing)
Fertiga doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fertiga shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fertiga in its N-PORT filings yet. We sweep new filings monthly.